C
Cheikh Diack
Researcher at Hoffmann-La Roche
Publications - 12
Citations - 112
Cheikh Diack is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Macular degeneration & Population. The author has an hindex of 5, co-authored 11 publications receiving 82 citations.
Papers
More filters
Journal ArticleDOI
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction.
Antonello Caruso,Matthias Füth,Rubén Alvarez-Sánchez,Sara Belli,Cheikh Diack,Katie F. Maass,Dietmar Schwab,Hubert Kettenberger,Norman A. Mazer +8 more
TL;DR: A model-based meta-analysis was conducted in humans and nonclinical species and mathematical formulae are presented that allow prediction of the ocular t½ for molecules of interest, successfully demonstrated in case studies of aflibercept, brolucizumab, and PEGylated Fabs, where the predicted t½ values are found to be in reasonable agreement with the experimental data available.
Journal ArticleDOI
Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function.
TL;DR: A Bayesian adaptive approach based on one binary response (occurrence of a DLE) and one continuous response (a measure of potential efficacy) per subject is described and evaluated, finding comparable performance to alternative approaches using efficacy and safety for dose‐finding.
Journal ArticleDOI
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
Wai Yin Yeung,Bruno Reigner,Ulrich Beyer,Cheikh Diack,Daniel Sabanés Bové,Giuseppe Palermo,Thomas Jaki +6 more
TL;DR: D dose-escalation designs that incorporate both the dose-limiting events and dose- Limiting toxicities (DLTs) and indicative responses of efficacy into the procedure are introduced.
Journal ArticleDOI
Bayesian adaptive designs in single ascending dose trials in healthy volunteers.
David Guédé,Bruno Reigner,Francois Vandenhende,Mike Derks,Ulrich Beyer,Paul Jordan,Eric Worth,Cheikh Diack,Nicolas Frey,Richard Peck +9 more
TL;DR: The new approach that includes Bayesian adaptive design in single ascending dose (SAD) trials conducted in healthy volunteers shows a very good performance in the estimation of MTD and in reducing the total number of healthy subjects.
Journal ArticleDOI
Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients
Dirk Jan A.R. Moes,Rogier R. Press,Oliver W. Ackaert,Bart A. Ploeger,Frederike J. Bemelman,Cheikh Diack,Judith A.M. Wessels,Tahar van der Straaten,Meindert Danhof,Jan-Stephan F. Sanders,Jaap J. Homan van der Heide,Henk-Jan Guchelaar,Johan W. de Fijter +12 more
TL;DR: Transplant-related factors remain the most important determinants of DGF, AR and SCR, and rejection treatment with depleting antibodies effectively prevented SCR in 6-month surveillance biopsies.